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Feedback regulation of nephron filtration rate during pharma-
cologic interference with the renin-angiotensin and adrenergic sys-
tems in rats. Tubuloglomerular feedback has been defined as a
mechanism in which changes in distal tubular sodium chloride
delivery induce changes in glomerular arteriolar resistance. Ex-
periments were performed in rats to test the hypothesis that the
alterations in vasomotor activity are controlled by local hormo-
nal mechanisms. Early proximal flow rate (EPFR), used as an
index of filtration rate, was assessed at loop perfusion rates of 10
and 40 nI/mm and during zero loop flow before and during intra-
venous administration of agents which interfere with the renin-
angiotensin or adrenergic systems. During infusion of the angio-
tensin (A) antagonists [Sar1,lle8]-AII or [Me2,Gly',Ile8]-AII at
doses ranging from 4.8 to 30.6 pg/kg mm, feedback response,
expressed as percent change of EPFR during ioop flow elevation
from 0 to 40 nllmin, fell from a mean of 47.6 3.3% to 33.2
2.9% (P < 0.05). Likewise, after administration of the converting
enzyme inhibitor SQ 20881 in a dose ranging between 5.5 and
34.0 mg/kg, feedback response decreased from 48.5 2.1% to
25.9 1.9% (P < 0.001) and returned to 43.1 .5.1% after the
inhibitory effect of SQ 20881 on the pressure response to angio-
tensin I had disappeared. Luminal application of [Sar',Thr]-AII
(5 mM) or of SQ 20881 (5 or 10 mM) had no effect on the feedback
response. A significant reduction in the feedback response was
noted also during intravenous infusion of propranolol
(46.4 3.2% vs. 29.0 2.8%, P <0.001), whereas 6-OH-dopa-
mine, reserpine, or phenoxybenzamine had no detectable effect.
Our results are in agreement with the concept that the renin-
angiotensin system may mediate feedback-induced resistance
changes. In addition, circulating catecholamines may, in some
unknown manner, act as modulators of the feedback response.
Regulation par feedback de Ia filtration glomerulaire au cours
d'interférences pharmacologiques avec le système refine-anglo-
tensine et le système adrenergique chez le rat. Le feedback
tubuloglomérulaire a été défini comme un mécanisme dans le-
quel Ic charge de sodium chloride délivrée au distal determine
des modifications de Ia résistance ai-tériolaire glomerulaire. Des
experiences ont été réalisèes pour verifier l'hypothese scion la-
queue les modifications de l'activité vaso-motrice sont con-
trólées par des mécanismes impliquant des hormones locales.
Le debit proximal précoce (EPFR), utilise comme un index de
debit de filtration, a été évalué a des debits de perfusion de
l'anse de 10 et 40 nI/mm et au cours de l'absence de perfusion de
l'anse, cela avant et après l'administration par voie intraveineuse
d'agents qui interférent avec les systémes renine-angiotensine et
adrénergique. Au cours de l'administration des antagonistes de
l'angiotensine (A) [Sar1, Ile8J-AII ou [Me2, G1y1,Ile8}AII a des
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doses allant de 4,8 a 30,6 pg/kg mm, Ia réponse de feedback,
exprimée en pourcentage de modification d'EPFR durant
l'augmentation du debit de perfusion de l'anse de 0 a 40 nI/mm, a
diminue de 47,6 3,3% a 33,2 2,9% (P <0,05). Dc la méme
facon, après l'administration de I'inhibiteur de l'enzyme de con-
version, SQ 20881, a des doses de 5,5 a 34,0mg/kg, la réponse de
feedback a diminué de 48,5 2,1% a 25,9 1,9% (P <0,001)
puis est revenue a 43,1 5,1% après que l'effet inhibiteur de SQ
20881 sur Ia réponse pressive a l'angiotensmne I ait disparu.
L'application luminale de [Sar1,Thr8]-A1I (5 mM) ou de SQ 20881
(5 ou 10 mM) n'a pas d'effet sur le feedback. Une diminution
significative de la réponse de feedback est observée aussi au
cours de l'administration intraveineuse de propranolol (46,4
3,2% au lieu de 29,0 2,8%, P <0,001) alors que Ia 6-OH-dopa-
mine, la réserpine, la phenoxybenzamine n'ont pas d'effet deed-
able. Nos résultats sont en accord avec le concept scion lequel le
système renine-angiotensine peut étre Ic mediateur des modifi-
cations de resistances induites par feedback. Dc plus, les caté-
cholamines circulantes peuvent, d'une facon encore inconnue,
agir comme modulateurs de cette réponse.
The mechanisms regulating GFR in different
states of salt balance and during variations of arteri-
al pressure are not understood in detail. There is
substantial experimental evidence that single neph-
ron glomerular filtration rate (SNGFR) is, in part,
regulated by a tubuloglomerular feedback system.
Thurau and Schnermann [1] and Schnermann et al
[2], as well as others [3—5] have shown that increas-
es in sodium chloride delivery to the ioop of Henle
are followed by reductions in SNGFR in the same
nephron. Accordingly, they proposed that altera-
tions in fluid composition in the macula densa re-
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gion of the nephron initiate a change in vasomotor
tone which leads to an inverse variation in SNGFR.
Since renin synthesis is localized in the juxtaglo-
merular apparatus, it is conceivable that the renin-
angiotensin system is a local mediator of feedback-
dependent changes in arteriolar resistance. Little
experimental evidence, however, supports this the-
ory. The availability of specific antagonists to an-
giotensin (A) [6] and of agents which interfere with
the conversion of Alto All [7, 8] provided a phar-
macologic means of assessing the potential contri-
bution of angiotensin to the feedback control of
SNGFR. In the present experiments, therefore, we
have determined the magnitude of feedback re-
sponse during pharmacologic interference with an-
giotensin formation or its action at receptor sites.
Methods
The experiments were performed on male
Sprague-Dawley rats. Each rat weighed between
175 and 385 g and was fed a standard diet (Altromin,
West Germany) containing 0.1 mEq of sodium per
gram of body weight. Anesthesia was induced by
sodium thiobarbital (mactin, 115 mg/kg, i.p.). Three
polyethylene catheters were placed into an external
jugular vein for infusion of isotonic saline at a rate
of 0.3 to 0.5 mllhr per 100 g of body weight and for
injection of drugs. Arterial blood pressure was mea-
sured continuously in a carotid artery with a Stat-
ham transducer and recorded with a Metrawatt
compensation recorder. A polyethylene tube was
inserted into a tracheal incision. Body temperature
was kept at 37 to 38° C by placing the animals on a
servo-regulated heating pad. The left kidney was
exposed through a flank incision, freed from pen-
renal connections, and placed with the capsule in-
tact into a lucite holder. The kidney surface was
covered with warmed (38° C) mineral oil. The ure-
ter was cannulated with polyethylene tubing.
The following micropuncture protocol, as illus-
trated in Fig. 1, was used in all experiments. A ran-
dom proximal segment was punctured with an 8-
tipped pipette, which was connected to a micro-
perfusion pump and contained stained modified
Ringer's solution. When the sequential coloration
of several tubular segments indicated an early prox-
imal tubular puncture site, this pipette was with-
drawn and inserted into the last proximal segment
of the identified nephron (Fig. 1, A). It was through
this pipette that alterations in the loop of Henle flow
rate were achieved.
A iSp-tipped pipette was inserted into one of the
intermediate proximal segments, and tubular flow
B A C
was blocked by injection of a highly viscous silicone
oil (Fig. 1, B). When no collection was made, leak-
age of tubular fluid occurred through the puncture
hole made by the identification pipette. The most
proximal segment of the identified tubule was punc-
tured with an 8 to 9p-tipped pipette (Fig. 1, C), and
a timed collection of early proximal tubular fluid
was made after injection of a mineral oil block of
conventional length. During this collection period,
the loop of Henle was perfused at either 10 or 40 nI/
mm through the pipette placed in the last proximal
segment (Fig. 1, A). Loop of Henle perfusion rate
was then either increased to 40 or reduced to 10 nIl
mm, and a second collection was done at the same
puncture site. Again, a small oil block was injected
to insure adequacy of collection. Note that collec-
tion and perfusion sites are separated by two inde-
pendent oil blocks with an interposed tubular seg-
ment. After absorption of the trapped tubular fluid,
this segment prevented retrograde pressure trans-
mission from the perfusion site even when the distal
silicone oil block moved into an upstream direction.
Absence of pressure transmission was indicated by
the free mobility of the proximal oil block. A'third
collection was made after removing the perfusion
pipette. Early proximal tubule fluid collection was
in almost every circumstance spontaneous. The op-
Fig. 1. Schematic drawing of microperfusion protocol where pi-
pette A is the perfusion pipette; B, the pipette used for the injec-
tion of oil block; and C, the collection pipette. Arabic 1 denotes
glomerulus; 2, proximal convoluted tubule; 3, ascending limb of
the loop of Henle; and 4, juxtaglomerular apparatus.
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eration of the microperfusion pump was checked by
repeated in vitro calibration. No in vivo calibrations
were performed in this experimental series. Since
our conclusions are based on the use of a flow rate,
which is clearly above that associated with a maxi-
mum feedback response, substantial deviations
from the set rate of 40 nllmin could be tolerated. A
change of flow rate in the actual experiment was in-
dicated by variations in the diameter of the late
proximal segments, by a tendency of the silicone oil
block to change its position, and by a change in di-
ameter and coloration of surface distal tubular seg-
ments. Proximal collections were only performed
when at least one of these criteria was clearly visu-
alized. The number of tubules studied in each kid-
ney varied between two and seven. The volume of
the collected fluid samples was determined in a con-
stant bore microcapillary. Earlier experiments have
shown that changes of nephron filtration rate are
closely reflected by changes of early proximal flow
rate (EPFR) [2, 3, 9]. Therefore, tubular fluid to
plasma inulin ratios were not determined in the
present study. The perfusion fluid used in all experi-
ments was a modified Ringer's solution consisting
of 135 m sodium chloride, 4 m sodium bicarbo-
nate, 4 m potassium chloride, 2 m calcium chlo-
ride, and 7.5 mrvi urea. One hundred milliliters of
this solution was colored by adding 1 ml of a 10 g/
100 ml solution of FD&C green (Keystone, USA).
In certain experiments, 5 or 10 mrvi SQ 20881 or 5
mM [Sar1, Thr8]-AII were added to the perfusion
fluid.
A few of the present studies were performed ac-
cording to the protocol outlined above with the ex-
ception that EPFR was assessed only at two ex-
treme conditions of loop flow (0 and 45 nllmin). In
another group of tubules, the direction of flow was
reversed by inserting the perfusion pipette into a
distal tubular segment and occluding the distal tu-
bule towards the collecting duct with an oil block.
The perfusate was continuously collected at a late
proximal puncture site. A detailed description of
this technique was given recently [10]. EPFR was
measured at 0 nllmin and at 20 nhlmin, a rate suf-
ficient to yield the maximum response in this per-
fusion protocol [11].
To compare the efficiency of the feedback system
between the control and the experimental condi-
tion, we expressed the feedback response as the
percent change in early proximal flow rate when
perfusion rate was raised from 0 to 40 or from 10 to
40 nllmin, respectively. This percent change was
calculated according to the following formula:
= (EPFR00r 10 — EPFR4IEPFRoor 100
where % is the percent change, and EPFR is at 0,
10, or 40 nllmin. There was no difference in feed-
back response whether 10 or 40 nhlmin was chosen
as the initial perfusion rate. The combined values
from all rats receiving a particular treatment were
subjected to variance analysis or to Student's t test
[12]. The 0.05 level of probability was used as the
criterion of significance. The feedback response
was characterized under the following three pro-
tocols:
Angiotensin antagonists. The effect of either
[Me2,G1y1,I1e8}AII or [Sar1,Ile8]-AII on the feed-
back response was studied in six rats. These ana-
logs of angiotensin block the pressor and myotropic
activity of angiotensin [3]. After the feedback re-
sponse in several control tubules was determined,
the pressor response to injections of AT, All, and
norepinephrine (in 0.01 or 0.02 ml of saline followed
by a 0.01 ml saline flush) was determined. The an-
giotensin antagonist was then infused in doses rang-
ing between 4.8 and 30.6 g/kg/min. The inhibitory
effect of the antagonist was verified by recording
the blood pressure response to another set of injec-
tions of AT and All. Thirty minutes after starting the
antagonist infusion, the feedback response was
again assessed by measuring changes in EPFR in a
number of different tubules. In two rats, [Sar1,
Thr8]-AII in a concentration of 5 m was added to
the perfusion solution. The analog was not infused
intravenously during the intraluminal perfusion.
Converting enzyme inhibitor. The ability of the
converting enzyme inhibitor SQ 20881 to influence
the feedback response was studied in ten rats. After
control feedback responses were obtained in three
to five tubules, SQ 20881 was administered in doses
ranging between 5.5 and 34 mg/kg, i.v. Approxi-
mately 30 mm later, the magnitude of the feedback
response was again determined in three to six neph-
rons. The effectiveness of SQ 20881 in inhibiting the
conversion of Alto All was determined by injecting
Al. A pressor response to norepinephrine served as
a control. In three rats the feedback response was
also measured after the SQ 20881-induced inhibition
of the conversion of Alto All had disappeared. In
another group of rats a possible effect of SQ 20881
when given from the luminal side was investigated
by adding this drug to the perfusate in concentra-
tions of 5 m (two rats) and 10 m (two rats). In
these experiments, SQ 20881 was not infused intra-
venously.
Catecholamine studies. The effect of certain
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drugs that interfere with the storage and release
of catecholamines on the feedback response was
studied in five groups of rats. In the first group of
three rats, the feedback response was measured in
rats pretreated with 6-hydroxydopamine (1 mg/kg,
i.p., given 7 and 1 day prior to the experiment). The
pressor response to tyramine was used to assess the
effect of 6-hydroxydopamine on adrenergic nerve
terminals. The second group of four rats was pre-
treated with alpha-methyldopa (3% in drinking wa-
ter for 4 weeks plus 200 mg/kg, i.p., daily for 7 days
before experiment). In the third group of two rats,
the rats were pretreated with reserpine (3.4 mg/kg,
i.p.) 48 and 24 hours prior to the experiment. In the
last two groups of rats, the feedback response was
characterized after alpha or beta blockade. To
achieve alpha blockade, we infused two rats with
phenoxybenzamine (3.7 and 5.9 mg/kg, i.v., for 30
mm) and one rat with phentolamine (0.68 mg'kg/hr,
i.v.). The pressor response to norepinephrine was
used to determine the degree of systemic blockade.
The beta-blocking agent propranolol (2 mg/kg, fol-
lowed by 750 pjg/kg/hr) was used in the final group
of four rats. The pressor response to isoproterenol
was used to assess the degree of blockade.
The following vasoactive agents were used: Al,
[Sar1,Ile8]-AII, [Me2,Gly 1,11e8]-AII, and [Sar1,Thr8]-
All (synthetized by Drs. Khosla and Bumpus, The
Cleveland Clinic Foundation), SQ 20881 (supplied
by Drs. Rubin and Cushman, The Squibb Institute),
norepinephrine bitartrate (Schuchardt), tyramine,
6-hydroxydopamine (Hoffman-LaRoche), phenoxy-
benzamine (Smith-Kline-French), phentolamine
and All amide (Ciba), aipha-methyldeoxy-phenyl-
alanine (Alpha-methyldopa®, Bayer), propranolol
(ICI-Pharma), reserpine, and isoproterenol (Boeh-
ringer).
Results
Angiotensin antagonists. In the experiments in
which the angiotensin antagonists [Me2,Gly',11e8]-
All and [Sar1,Ile8]-AII were infused intravenously,
the pressor response to All was tested before and
30 mm after beginning the infusion of the antago-
nists. An example of a record showing the systemic
inhibition of the pressor response to All by
[Me2,Gly1,11e8]-All (4.8 pg/kg . mm) is given in Fig.
2. A blockade of the pressor response to All similar
to that demonstrated in Fig. 2 was noted in all the
experiments in which the effect of the antagonists
on the feedback response was studied. Since both
analogs appeared to have similar antagonistic prop-
erties, results were summarized together. Blood
pressure averaged 112.8 4.6 mm Hg (N = 6) dur-
ing the control period and 102.8 3.4 mm Hg (N =
6) during infusion of the antagonists. These values
were not significantly different from each other.
The changes in EPFR before and during the ad-
ministration of the antagonists are presented in
Table I. The mean percent reduction in EPFR dur-
ing the control period was 47.6 3.3% when flow
was elevated from 0 to 40 nllmin and 44.3 3.8%
when flow was raised from 10 to 40 nI/mm. During
systemic blockade of the pressor response to All,
the percent reduction of EPFR was reduced to 33.2
2.9% and 29.3 2.6% when perfusion rate was
raised from 0 to 40 and 10 to 40 nllmin, respectively.
These reductions in EPFR were significantly dif-
ferent from control (P < 0.05). A dose-response
relationship was not apparent in these data. On the
contrary, it appeared as if higher doses were associ-
ated with smaller inhibitory effects.
The individual values for EPFR from experiment
3 are presented diagrammatically in Fig. 3. Prior to
the infusion of the antagonist, EPFR decreased in
each of the five tubules tested when perfusion rate
was changed from either 10 to 40 nI/mm or 0 to 40
nllmin (34.1 10.6% and 39.7 8.7% decrease, re-
spectively). The change was less pronounced after
A All NE
ii
E
E
a,
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00
Fig. 2. Bloodpressure responses to angiotensin II (A II) and nor-
epinephrine (NE) bejbre (panel A) and during (panel B) the in-
fusion of [Me2, G1y1, 11e8j-AII(4.8 pg/kg mm).
lOng 2Ong lOOny
B All All NE
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Table 1. Changes in early proximal flow rate (EPFR) initiated by altering flow past the macula densa before (B) and during (D) the i.v.
administration of [Me2 Gly' 11e8J-AII (rats 1, 2, 3, 5) or [Sar5, Ilel-All (rats 4, 6) a
Ratno.
Dose antagonist
pg/kgmmn Period No. oftubules
Mean EPFR
ni/mm
Decrease in EPFRh
%
0
Pump setting
10 40
Pump setting
Oto4O lOto4O
1 4.8 B
D
2
2
19.1
18.4
17.0
15.1
10.9
10.6
49.6 9.5 43.4 9.3
42.8 2.1 30.1 1.3
2 5.4 B
D
4
3
23.0
32.8
22.8
30.9
10.6
18.7
56.3 10.3 54.4 11.6
42.7 4.4 39.2 4.6
3 6.0 B
D
5
3
25.6
30.2
23.5
29.9
16.2
26.6
39.7 8.7 34.1 10.6
11.9 0.7 10.8 0.4
4 10.5 B
D
4
5
25.4
28.4
24.1
27.6
12.7
18.2
50.7 7.0 47.1 8.7
35.9 6.5 33.6 6.9
5 17.9 B
D
4
4
23.2
22.5
22.5
21.4
14.4
15.2
38.0 6.3 35.8 5.8
31.9 2.8 29.3 1.6
6 30.6 B
D
4
4
28.6
29.2
28.2
26.9
13.2
18.7
54.1 4.5 53.4 5.1
35.4 6.7 29.8 5.5
Mean SEM B
D
23
21
24.7
27.4
23.6 13.2
25.9 18.3
47.6 3.3 44.3 3.8
33.2 2.9c 29.3 2.6a
10, and 40 nI/mm.a Macula densa flow was varied by perfusing loops of Henle at 0,
h The feedback response is expressed as the percent reduction of EPFR when loop of Henle flow was elevated from 0 to 40 nI/mm (0 to
40) or from 10 to 40 nI/mm (10 to 40).
Values are significantly different from control values (B), P <0.05 (analysis of variance, unweighted means).
50 ,—
the antagonist administration, with only a 10.8
0.4% decrease when going from 10 to 40 ni/mm and
an 11.9 0.7% decrease when going from 0 to 40 nIl
mm. This represents an inhibition of the feedback
response of approximately 69%. Percent inhibition
of the feedback response (FR) was calculated from
(FRcontro1 — FRirugIFRontro) x 100.
The effect of luminal application of 5 mM
[Sar',Thr8]-AII is summarized in Table 2. During
orthograde loop of Henle perfusion with the control
solution, EPFR fell by 37.9 3.5%. In the presence
of the antagonist, the reduction was not significant-
ly different from control (33.9 3.9%). When the
loop of Henle was perfused in a retrograde manner,
EPFR fell by 31.1 4.6% in the control and by 42.5
3.0% in the presence of the angiotensin antago-
nists. These values were significantly different from
each other (P < 0.05%). The six rats used in the
0 experiments which are summarized in Table 2 had a
mean body weight of 327 21 g and a mean kidney
weight of 1.14 0.08 g. These values are sub-
stantially higher than those found in all other exper-
imental series are and explain the greater EPFR at
zero loop perfusion.
40
30
20
10
PC
E
0
a
>
uJ
Perfusion rate, ri//rn/ft
Fig. 3. Early proximal flow rates obtained at loop of Henle per-
fusion rates of 10, 40, 0 ni/mm before (open circles) and during
(black squares) infusion of [Me2, G1y1, 11e8]-A!1 (6 ug/kg.min).
The diagram presents results from mndividual tubules in experi-
ment 3, Table 1.
10 40
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Table 2. Feedback response of early proximal flow rate during alterations in orthograde (0 to 45 ni/mm) or retrograde (0 to 20 nI/mm) loop
of Henle flow ratesa
During orthograde perfusion
ni/mm
During retrograde perfusion
ni/mm
0 45 0 20
N nhlmin ni/mm % Change N nI/mm ni/mm % Change
Control 6 43.0 32.7 —24.1 6 43.7 32.3 —26.8
6 44.6 32.8 —25.5 10 42.1 33.9 —20.1
Control 4 41.2 27.2 5 36.6 21.1 —43.9
10 mM SQ 20881 7 39.2 27.4 —29.7 7 47.3 33.6
5 5
5 mM [Sar', Thr8]-A11 8 36.8 24.5 —33.9 9 41.8 24.4 —42.5k
a The drugs were added to the Ringer's solution used to perfuse the loop of Henle. Values represent mean response SEM.
Values are significantly different from control values (P <0.05, Student's (test).
Converting enzyme inhibitor. SQ 20881 inhibits
the conversion of AT to All [7, 8]. The effectiveness
of this inhibition under our experimental conditions
was tested in every single animal by recording the
pressure response to Al and All. An example of
this inhibition is shown in Fig. 4 where the upper
panel represents the control pressure responses.
During the administration of SQ 20881, the pressure
response to Al, but not that to All, was inhibited
(Fig. 4, panel B). A significant systemic inhibition of
the pressor response to Al was noted after giving
SQ 20881 in all experiments listed in Table 3.
EPFR's at perfusion rates of 0, 10, and 40 nllmin
are averaged in Table 3 regardless of the dose or
manner of administration of SQ 20881. Before the
drug was given, EPFR was 25.0 1.0 nllmin at 0
flow, 24.1 1.1 nhlmin at a flow rate of 10 nllmin,
and 13.9 0.9 nllmin at 40 nhlmin. During the ad-
ministration of SQ 20881, EPFR was 28.3 1 nIl
mm at 0 flow, 27.6 1.1 nllmin at 10 nllmin, and 20.8
0.9 nllmin at 40 nllmin. Thus, when flow was ele-
vated from 0 to 40 nllmin, percent reduction of
EPFR equaled 48.5 2.1% before and 25.9 1.9%
during the action of SQ 20881. It is to be noted that
the feedback response was blunted by SQ 20881 in
every single one of the ten experiments presented.
SQ 20881 was administered in two different ways.
In experiments 1 through 7, one half of the total
dose presented in Table 3 was given in 1 ml of sa-
line, i.v., over a 4-mm period, and the remaining
half of the dose was added to the saline infusion (in-
fusion rate 0.5 mlllOO glhr). Micropuncture was
started about 45 mm later. To examine a possible
dose-dependency relationship between SQ 20881
and the feedback response in the first seven experi-
ments (Table 3), we plotted the percent decrease in
EPFR during flow elevations from zero to 40 nhlmin
in Figure 5 against the dose of SQ 20881. In contrast
ut
5Ong lOOng 5ng 1 ngA Al Al All All
:: •
100 ng 200 ng 5 ng 10 ng
B Al Al All All
I I I I I
I,
5n9 lOng
All AII
Fig. 4. Pressor responses to angiotensmn I (A!) and angiotensin II
(All) before (panel A), 90 mm after the administration of SQ
20881, 20 mg/kg, iv. (panel B), and 180 mm after SQ 20881 (panel
C).
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Table 3. Changes in early proximal flow rate (EPFR) initiated by altering flow rate past the macula densa before (B), during (D), and after
(A) the i.v. administration of SQ 20881a
Rat no.
Dose
SQ 20881
mg/kg Period No. of tubules
Mean EPFR
ni/mm
Decrease in EPFRb
%
0
Pump setting
10 40
Pump setting
0 to 40 10 to 40
1 5.5 B
D
4
5
24.8
23.6
23.7
23.2
8.8
13.7
65.3 3.1 62.6 3.1
41.9 4.2 41.3 3.3
2 5.6 B
D
4
5
25.2
25.2
23.9
24.6
14.4
17.9
42.1 3.2 39.1 3.2
29.1 3.7 29.5 3.8
3 7.9 B
D
3
5
26.2
33.3
24.9
31.4
15.6
26.4
40.6 5.8 37.5 4.7
20.5 4.8 16.2 3.3
4 9.0 B
D
4
5
18.8
20.0
17.0
19.6
7.5
16.9
60.2 5.1 55.4 6.0
15.5 5.1 14.2 4.7
5 11.6 B
D
4
6
26.3
29.5
25.1
29.2
11.4
20.3
56.8 3.8 53.5 4.4
32.2 6.0 31.3 5.5
6 14.7 B
D
4
3
28.7
41.3
28.0
43.0
15.4
30.2
46.1 4.4 45.1 4.6
26.5 2.2 12.9 4.4
7 15.1 B
D
4
3
28.0
30.9
27.0
29.2
14.5
25.4
47.8 6.2 46.5 4.8
19.0 2.2 12.9 4.4
8 19.6 B
D
A
4
5
3
25.3
31.4
27.7
24.8
30.7
28.7
16.6
23.0
14.5
35.5 5.5 34.2 4.1
26.8 4.7 25.5 2.9
48.7 9.7 47.5 7.5
9 21.6 B
D
A
5
4
3
28.7
30.2
28.2
28.7
29.0
27.8
16.2
23.2
14.5
46.6 8.7 46.2 8.4
17.0 7.2 17.4 4.4
47.6 3.9 48.5 3.7
10 34.0 B
D
A
4
4
3
17.9
22.5
11.1
17.2
21.6
11.4
10.4
16.6
7.5
42.2 2.0 39.8 1.3
24.7 6.0 21.6 6.5
36.0 13.3 33.3 15.7
Mean SEM B
D
A
40
45
9
25.0
28.3
22.3
24.1
27.6
22.6
13.1
20.8
12.2
48.5 2.1 46.2 2.0
25.9 1.9e 24.4 l.8c
43.1 5.1 44.1 5.3
and 40 nI/mm.a Macula densa flow was varied by perfusing loops of Henle at 0, 10,
b The feedback response is expressed as the percent reduction of EPFR when loop of Henle flow was elevated from 0 to 40 nI/mm (0 to
40) or from 10 to 40 nI/mm (10 to 40).
eValues are significantly different from control values (B), P <0.001 (analysis of variance, unweighted means).
to Table 3 where only mean values are presented,
Fig. 5 shows the results from each tubule in the con-
trol period (0 dose of SQ 20881) and after the admin-
istration of SQ 20881 (5.5 to 15.1 mg/kg). The pre-
sentation of these results in this manner demon-
strated a negative relationship (r = — 0.735, P <
0.001) between the magnitude of the percent de-
crease in EPFR and the dose of SQ 20881. When
loop of Henle flow rate was increased from 0 to 40
nllmin in the control situation (0 dose SQ 20881),
EPFR decreased by 48.5 2.1%. SQ 20881 blunted
this response in a dose-related manner. The percent
inhibition ranged between 31 and 74%.
In experiments 8 through 10, the feedback re-
sponse was studied in a control, in an experimental,
and in a recovery period. The total dose of SQ
20881 listed in Table 3 for experiments 8, 9, and 10
was administered intravenously in a 1-mi volume of
saline over a 5-mm period. Micropuncture was
started about 40 mm later (experimental period).
Approximately 180 to 220 mm later, the SQ 20881-
induced inhibition of the pressure response to Al
had vanished, and micropuncture was resumed (re-
covery period). The percent decrease of EPFR pri-
or to, during, and after the systemic action of SQ
20881 in these three experiments is summarized dia-
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0-40 10-40
Control
0-40 10-40
SQ 20881
0-40 10-40
Recovery
N= 13 N=13 N—9
Fig. 6. Feedback response to a change in loop of Hen/c flow rate
from 0 to 40 ni/mm (0—40, white columns) or from 10 to 40 nI/mm
(10-40, dotted columns) before (control), daring (SQ 20881, 19-
34 mg/kg iv.), and after the (recovery) SQ 20881 reversibly in-
duced inhibition of the conversion of angiotensin Ito II. Column
heights represent mean responses SEM, and N is the number of
tubules in three rats.Asterisk denotes P <0.001, analysis of vari-
ance, unweighted means.
grammatically in Fig. 6. During the experimental
period, the mean percent reduction in EPFR when
flow was elevated from 0 to 40 nllmin was 41.8
3.7%. Following the administration of SQ 20881,
the mean percent reduction in EPFR was 21.8
2.6%, a value significantly different from the control
value (P < 0.05). The feedback response in the re-
covery period was 43.1 5.7%, a value not dif-
ferent from the control. Thus, the inhibition of the
feedback response by SQ 20881 was fully revers-
ible. Mean blood pressure was 121 3.0mm Hg (N
= 10) during control, 110.9 2.3mm Hg (N = 10)
during the infusion of SQ 20881 (P < 0.05), and
108.9 6.2 mm Hg (N = 3) during the recovery
period. As shown in Table 4, GFR was not altered
by SQ 20881 at two different doses. There was a
tendency for sodium excretion to increase due to an
increase in urinary sodium concentration without a
change in urine volume.
Results of the effect of luminal application of SQ
20881 are presented in Table 2. During orthograde
perfusion with solutions containing SQ 20881,
EPFR fell by 25.5 4.1% (control, 24.1 2.2%)
with the 5 m solution and by 29.7 4.5% (control,
34.7 8.8) with the 10 m solution. Retrograde
perfusion reduced EPFR by 20.1 2.4% (control,
26.8 6.0%) when the 5 m solution was used and
by 30.9 4.6% (control, 43.9 8.3%) when the 10
m solution was used. In no instance was there a
significant difference between the control and SQ
20881 luminal perfusion values.
Catecholamine studies. To test the possible par-
ticipation of catecholamines in the feedback regula-
tion of SNGFR, we studied alterations in EPFR in
response to changes in loop of Henle flow rate after
administering various drugs which interfere with
the synthesis, storage, or receptor action of cate-
cholamines. The effect of drugs that interfere with
the adrenergic nervous system on the feedback re-
sponse is presented in Table 5. Five differently
treated groups were studied.
In the first protocol, the feedback response was
tested in three rats pretreated with 6-hydroxy-
dopamine, which is known to destroy the adrener-
gic nerve terminals [13]. The effectiveness of the
treatment was assessed by measuring the pressor
response to tyramine. Tyramine at 50 g did not in-
duce a change of blood pressure, but 100 j.g of the
agent increased mean blood pressure slightly by 5
1 .0 mm Hg. Feedback response, expressed as per-
cent reduction of EPFR during a flow elevation
from 0 to 40 nllmin, was 40.1 2.4%. This value is
80 r —0.735N 59
P <0.001
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Fig. 5. Dose-response relationship between the percent decrease
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Table 4. Effect ofSQ 20881 in two different doses and of propranolol on GFR , urine flow, and sodium secretiona
GFR V UNaV [Na]
mi/mm g p1/mm mEq/min mEq/liter
Control (N = 3) 1.11 0.13 9.82 1.99 0.49 0.19 52.7 17.6
10 mg SQ 2088lb (N = 3) 0.97 0.09 10.6 0.51 0.97 0.24 114.3 18.5
Control (N = 3) 0.78 0.08 7.35 3.3 0.51 0.35 52.8 15.1
20 mg SQ 2088l' (N = 3) 0.78 0.04 8.63 4.61 1.14 0.84 104 28.2
Control (N = 4) 1.03 0.06 2.8 0.43 0.22 0.08 76.2 15.3
PropranoloV'(N = 4) 1.1 0.13 8.7 2.8 1.43 0.36 180.8 24.8
a Values represent the means SEM. Abbreviations are defined as V, urinary volume; UNaV, sodium excretion; [Na], sodium concentra-
tion. N denotes number of rats used.
b The doses of SQ 20881 were given, in the amount indicated, per kilogram of body weight. Propranolol was given at a dose of 2 mg/kg
while at the same time it also was infused at the rate of 750 pg/kg/hr.
TableS. Theeffect ofvarious treatments on changes in early
proximal flow rate (EPFR) initiated by altering flow rate past the
macula densaa
Treatment
No. of
rats
No. of
tubules
Decrease in EPFRb
%
Pump setting
0 to 40 10 to 40
6-}{ydroxydopamine
a-Methyl dopa
Reserpine
Alpha blockade
Phenoxybenzamine
Phentolamine
Mean response
3
4
2
2
1
3
21
11
7
5
3
8
40.1 2.4 40.3 2.4
49.8 4.3 44.2 2.4
41.8 7.8 41.1 7.9
59.7 6.1 52.5 7.3
45.8 7.8 40.3 6.8
54.5 5.1 47.9 5.4
a Values represent mean responses SEM.
The feedback response is expressed as the percent reduction
in EPFR when 1oop of Henle flow as elevated from 0 to 40 nI/mm
(0 to 40) or from 10 to 40 nI/mm (10 to 40).
in the range of the control values reported in earlier
studies [9, 10] and is not significantly different from
the mean feedback response of 46.7 1.5% noted
in the preexperimental periods in the present work.
Mean blood pressure was somewhat lower (93.5
4.3 mm Hg, N = 3) than what is usually encoun-
tered in untreated rats.
The effect of pretreatment with alpha-methyl
dopa was studied in four rats in the second pro-
tocol. The feedback response was not affected by
this treatment. There was a 49.8 43.% reduction
for the 0 to 40 nllmin flow change and a 44.2 2.4%
reduction for the 10 to 40 nI/mm change. Again,
these values are within the control range. Blood
pressure averaged 116 2.6 mm Hg (N = 4) in this
group.
In the third group of rats, the feedback response
was elicited in two rats pretreated with reserpine.
At the 0 to 40 nI/mm flow change, the percent reduc-
tioninEPFRwas4l.8 7.8%and4l.4 7.9%for
the 10 to 40 nI/mm change. These values are also
within the normal range.
The effectiveness of alpha blockade in inhibiting
the feedback response was tested in three rats in the
fourth group. Phenoxybenzamine was given to two
rats. Norepinephrine was injected to assess the de-
gree of alpha blockade. Phenoxybenzamine at the
doses used did not inhibit the feedback response.
The percent reduction in EPFR was 59.7 6.1% for
the 0 to 40 nI/mm flow change and 52.5 7.3% for
the 10 to 40 nI/mm change. Another alpha blocker,
phentolamine, was infused intravenously in one rat.
The feedback response was not measureably al-
tered by this dose of phentolamine. The percent re-
duction in EPFR was 45.8 7.8% for the 0 to 40 nIl
mm flow rate and 40.3 6.8% for the 10 to 40 nI/mm
change. When the experiments involving alpha
blockers were combined, the percent reduction in
EPFR was 54.5 5.1% for the 0 to 40 nllmin change
and 47.9 5.4% for the 10 to 40 nI/mm change.
Since these figures are similar to our overall control
values (46.7 1.5% and 45.9 1.6%), alpha block-
ade, in the dosage used, did not affect the feedback
response. Attempts to use higher doses of the alpha
blockers resulted in a fall in systemic blood pres-
sure below 100 mm Hg.
In the final group, the effect of the beta blocker
propranolol on the feedback response was studied
in four experiments as presented in Table 6. After
control responses were obtained, propranolol (2
mg/kg, i.v.) was given over a 10-mm period. At the
same time, propranolol also was infused at the rate
of 750 j.g/kg/hr, i.v. Systemic beta blockade was as-
sessed by measuring the response to isoproterenol.
Approximately 100 mm after the administration of
propranolol, the magnitude of the feedback re-
sponse was assessed again. At this time, 100 ng of
isoproterenol did not cause any drop in blood pres-
sure. The pressure responses to All and norepi-
nephrine were still present at a time when the hypo-
tensive response to isoproterenol was inhibited. Pri-
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Table 6. Changes in early proxim
ad
al flow rate (EPFR) initiated by altering flow past the macula densa before (B) and during (D) the i.v.
ministration of propranolol (2 mg/kg, i.p., followed by 750 g/kgIhr).a
Rat no. Period
Mean EPFR Decrease in EPFR5
ni/mm %
Pump setting Pump setting
No. of tubules 0 10 40 0 to 40 10 to 40
1
2
3
4
Mean SEM
B
D
B
D
B
D
B
D
B
D
4 21.4 20.2 12.4 43.9 8.2 40.5 6.0
4 31.4 29.8 20.9 33.6 5.1 30.4 5.5
4 24.2 22.5 14.4 40.2 6.7 35.3 8.2
4 30.6 30.2 23.8 22.4 4.6 21.0 5.2
4 26.2 25.6 14.2 45.2 2.5 43.0 5.1
4 28.0 28.8 20.8 27.9 8.6 31.4 11.2
3 21.5 21.1 8.7 59.5 2.5 59.3 3.3
5 25.6 26.3 17.3 31.5 4.1 32.0 6.2
15 23.4 22.4 12.6 46.4 3.2 43.6 3.6
17 28.7 28.6 20.5 29.0 2.8c 28.9 35c
Macula densa flow was varied by perfusing loops of Henle at 0, 10, and 40 nI/mm.
The feedback response is expressed as the percent reduction of EPFR when loop of Henle flow was elevated from 0 to 40 ni/mm (0 to
40) or from 10 to 40 nI/mm (10 to 40)
Values are significantly different from control values (B), P < 0.001 (analysis of variance, unweighted means).
or to the administration of the drug, the percent
reduction in EPFR at the 0 to 40 nI/mm and 10 to 40
ni/mm perfusion rate steps were 46.4 3.2% and
43.6 3.6%, respectively. After propranolol, the
corresponding percent changes were only 29.0
2.8% and 28.9 3.5%. This represents a significant
inhibition of the feedback response (P < 0.001) of
approximately 35%. Mean control blood pressure of
120.4 2.46 mm Hg (N = 4) fell to an average of
106 4.2 mm Hg (N = 4, P < 0.05). Whereas GFR
did not change during propranolol administration,
there was a significant increase in urinary sodium
excretion and sodium concentration (Table 4).
Discussion
It is well established that the formation rate of
glomerular filtrate in single tubules is inversely re-
lated to the flow of fluid entering the loop of Henle
[2, 3, 14]. Thus, it appears that each nephron pos-
sesses a regulating device at a late tubular site con-
structed to maintain distal delivery of fluid in nar-
row boundaries. Since feedback-induced changes in
SNGFR are accompanied by changes of glomerular
capillary pressure [3, 15], adjustments of glomerular
arteriolar resistance are at least partly responsible
for the resetting of GFR. At the present time, there
is a little experimental evidence to indicate which
factors are largely responsible for the alteration of
glomerular arteriolar tone.
Anatomic evidence strongly suggests that the in-
formation used in feedback control of SNGFR is
processed at the level of the juxtaglomerular appa-
ratus since this structure represents the only region
where a late tubular segment is systematically ad-
herent to the glomerular pole of the same nephron
unit. Since the juxtaglomerular complex is also the
site of synthesis and storage of renin, it appeared
logical to implicate the renin-angiotensin system in
feedback control of glomerular arteriolar resistance
[16]. It is conceivable that in response to a flow-
dependent alteration in tubular fluid composition at
the macula densa, angiotensin is generated locally
and exerts its action on contractile elements of cells
belonging to the same glomerular unit without being
necessarily released into the blood stream. An ac-
tion of tissue-borne All appears feasible since all
constituents for local generation and degradation of
the vasoactive peptide are present in the juxtaglo-
merular apparatus [17-20]. Furthermore, the equal
activities of renin in renal arterial and peritubular
capillary blood at a time when renal venous renin
concentration was augmented [21] suggest that the
prime path of renin liberation is from the juxtaglo-
merular cells into the interstitium rather than into
the blood. The present experiments appear to sup-
port a role of angiotensin in feedback-induced
changes of arteriolar vasomotor tone. The feedback
response to identical flow rate changes was found to
be reduced in the presence of angiotensin antago-
nists or the converting enzyme inhibitor SQ 20881,
agents which are known to interfere with either an-
giotensin-smooth muscle interaction or with the for-
mation of All. It was the concept of an angiotensin
interaction with "interstitial" rather than vascular
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receptors which led us to use rather large doses of
the inhibitory agents. Local saturation of such sites
would require very high systemic concentrations to
achieve high interstitial concentrations of the drug.
To establish drug action, we tested the response
of blood pressure to an injection of angiotensins or
catecholamines before and during administration of
the inhibitors. That the reduced feedback response
is a consequence of acute volume expansion in-
duced by these test injections may be argued. Al-
though it has been shown that acute volume expan-
sion does reduce the magnitude of the feedback re-
sponse [22], greater volumes than those used in the
present experiments were required. Furthermore, a
change in feedback efficiency did not occur in the
rats treated with 6-hydroxydopamine, phenoxy-
benzamine, or reserpine. In these experiments, in-
jections of various test drugs were also done. Final-
ly, in a number of experiments with the converting
enzyme inhibitor, SQ 20881, reversibility of the in-
terference with the feedback response was demon-
strated even though test injections of Al were re-
quired to document the presence and absence of
converting enzyme inhibition. This result also ar-
gues against a systematic effect of time in reducing
the feedback response and coincides with a number
of earlier studies in which the magnitude of feed-
back responses was not changed over the time of a
micropuncture experiment [2, 10, 11, 15].
Although interference with the feedback re-
sponse induced by angiotensin antagonists or by
converting enzyme inhibition was a very reproduc-
ible event from animal to animal, it is noteworthy
that even with the highest doses we never observed
a complete inhibition such as that induced by man-
nitol [2, 15]. It is to be realized that blockade of the
blood pressure response to Al or All was used as
the only criterium for drug action. Thus, one cannot
be certain that doses sufficient to prevent All gener-
ation in the blood or to saturate vascular angioten-
sin receptors will suffice to inhibit angiotensin ac-
tion in the juxtaglomerular cell complex. The den-
sity of "interstitial" receptors and the local activity
of converting enzyme may be too high to permit ex-
travascular accumulation of All-antagonists or SQ
20881 in sufficient concentrations. It is also possible
that these peptides do not readily penetrate the arte-
riolar wall so that retarded diffusion to the site of
action limits their inhibiting effects.
It is possible that the failure of All-antagonists
and SQ 20881 to inhibit fully the feedback response
is indicative of a more complex mechanism of signal
transmission. It has been shown that SQ 20881 not
only inhibits angiotensin converting enzyme, but al-
so interferes with kininase activity, thus potentiat-
ing the action of bradykinin [7, 8]. Perhaps the feed-
back response is induced by a mechanism whereby
increased tubular flow leads to a reduction in the
rate of bradykinin generation. This may increase
glomerular arteriolar resistance and reduce gb-
merular capillary pressure and filtration rate. Con-
ceivably then, the presence of excess amounts of
bradykinin in the juxtagbomerular cell complex fol-
lowing kininase inhibition could reduce the effect of
a given flow rate change, resulting in a blunted feed-
back response. Presently, direct evidence that bra-
dykinin may be formed at the level of the juxtagbo-
merular apparatus is not available. Nevertheless,
stop-flow analysis indicates a distal site of origin of
urinary kallikrein, suggesting that bradykinin may
indeed accumulate in cells of the distal nephron
[23]. Participation of bradykinin in feedback-in-
duced vasomotion may explain the greater inhib-
itory effect of SQ 20881 compared to that of the an-
giotensin antagonists.
Because angiotensin analogs exert agonistic ef-
fects in high concentrations, that the reduction of
feedback efficiency is caused by an angiotensin-like
effect of these agents cannot be excluded. For in-
stance, angiotensin enhances the synthesis of pros-
taglandin E (PGE) in the kidney [24] so that it would
seem feasible that the blunted feedback response
may be related to a local vasodilatory action of POE2
partly antagonizing the feedback-induced vaso-
constriction. Increased synthesis of prostaglandins
may also result from the administration of SQ
20881. The augmented production of renal kinins
following SQ 20881 [25] could act as a stimulus for
renal PGE production [26]. In a large series of re-
cent experiments, however, we have noted that
feedback responses are inhibited during inhibition
of prostaglandin synthesis [27]. Thus, the effect of
prostaglandins in the feedback circuit does not ap-
pear to be related to their own vasoactive proper-
ties. We assume that PGE is indeed a vasodilator of
the rat kidney vasculature in situ [28], although Ma-
lik and McGiff have demonstrated a vasoconstrictor
response in isolated kidneys of this particular spe-
cies to PGE2 [29].
In addition to alternative interpretations of our Fe-
suits by assuming a multicomponent feedback
transmission system, there is the more general pos-
sibility that the reduction of the feedback response
observed during the action of converting enzyme in-
hibitors, angiotensin antagonists, or /3-blockers is
the consequence of unspecific hemodynamic
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changes induced by the intravenous administration
of the respective drugs. In particular, these agents
directly or indirectly may cause a renal vasodila-
tion, which in itself could reduce the influence of a
given change in distal solute delivery on filtrate for-
mation. In this case, feedback inhibition would not
occur through a change in signal transmission, but
would reflect the alteration in the dynamics of ultra-
filtration. Pertinent data from the literature suggest
that propranolol may elevate renal blood flow some-
what [30, 31], although this effect does not seem to
be demonstrable in all cases [32—34]. No effect of
SQ 20881 on renal blood flow was reported by Gag-
non et al [35, 36] in the dog. Moderate increases of
renal blood flow reported by other authors appear
to be almost exclusively restricted to the inner cor-
tical zones [37]. The observation of Stein et al [38]
that bradykinin induces a similar redistribution of
blood flow towards the inner cortex suggests that
the effect of SQ 20881 on blood flow is pre-
dominantly related to its action as a kininase inhib-
itor. Several reports agree that angiotensin antago-
nists induce renal vasodilation when plasma angio-
tensin levels are elevated above normal by chronic
sodium depletion or partial constriction of one renal
artery [39, 40]. These agents, however, do not affect
renal blood flow in anesthetized animals under con-
trol conditions [39—43]. Thus, we do not consider it
very likely that blood flow of the superficial renal
cortex was markedly elevated in our experiments.
In addition, even in the case that renal blood flow
had increased to some extent, it would be unclear
whether the inhibited feedback response was the
cause or effect of the changed blood flow.
Interference with tubuloglomerular feedback was
not observed when SQ 20881 or [Sar1, Thr8]-AII
was applied from the luminal side of the tubule. It is
well documented that peptides are rapidly de-
stroyed when added to the proximal tubular fluid
[44]. Nevertheless, lack of an effect during luminal
application was also noted in retrograde perfusion
experiments in which the distance between infusion
site and macula densa cells was greatly reduced.
Thus, we assume that diffusibility of these agents
across the macula densa cells is too low to reach the
site of angiotensin formation and action.
The present results add to the indirect evidence
that feedback-induced changes of vasomotor tone
may be angiotensin-mediated. First, it has been
shown that dissected glomeruli have an elevated re-
nm activity when their macula densa segments are
exposed to isotonic saline solution before removal
of the kidney [45]. If the in vitro assay mirrors an in
situ event, then the initiation of a feedback response
is accompanied by increased generation of angio-
tensin. Sodium bromide, however, does not induce
an elevation of renin activity [45], although it is as-
sociated with a normal feedback response [1, 11]. It
is unclear at present whether sodium bromide pro-
duces its effect through a pharmacologic mecha-
nism or whether activation of renin is not casually
related to the feedback response. Second, in some
situations the magnitude of the feedback response
correlates with juxtaglomerular renin activity. For
instance, in rats fed a high-salt diet and injected
with DOCA, both feedback response and renin are
greatly suppressed [9]. The same observation was
made in contralateral kidneys of Goldblatt hyper-
tensive rats, whereas in the clipped kidneys of these
rats the opposite was true; renin and feedback re-
sponse were greater than normal [46]. Even if these
results were undisputed, which they are not [47],
they would not be able, however, to make a strong
case for angiotensin mediation of feedback since a
great number of other variables are altered as well
in these animals.
Although our results provide new evidence for
the participation of the renin-angiotensin system in
mediating feedback-induced vasomotor activity, it
appears that the adrenergic system may also be in-
volved in some way. During beta-blockade with
propranolol, the feedback response was significant-
ly reduced whereas alpha-blockade had no effect. It
is unclear at present how catecholamines are in-
tegrated into the feedback circuit. Since neither de-
pletion of adrenergic nerve vesicles with reserpine
nor destruction of the terminals with 6-hydroxy-
dopamine exert a noticeable effect on the feedback
response, it appears that nervous transmission is
not directly involved in producing feedback-depen-
dent changes in glomerular resistance to flow. Inde-
pendence of tubuloglomerular feedback from sym-
pathetic influences is also supported by our recent
finding that isolated blood perfused dog kidneys ex-
hibit a normal feedback response [48]. It is possible,
therefore, that the feedback response is in some
way modulated by circulating catecholamines since
adrenal medullary catecholamine content is not
greatly modified by 6-hydroxydopamine [49] or re-
serpine [50].
Beta-receptors have been assigned a role in the
control of renin release [51]. Because the feedback
response was decreased by propranolol, one may
be tempted to interpret this observation as being a
consequence of reduced renin release. One must be
cautious, however, in directly relating the secretion
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of renin to its proposed role in the feedback circuit.
Renin secretion is equally affected by changes in
renal sympathetic discharge rate and by the level of
circulating catecholamines [51]. Thus, the effect of
sympathetic denervation or receptor blockade on
tubuloglomerular feedback should also be equal
which was not the case as shown in these experi-
ments. Furthermore, the correlation between renin
release and feedback response does not hold in oth-
er experimental situations. For instance, furose-
mide [52] as well as theophylline [53] are known to
produce an increased renin release, but at the same
time these agents also inhibit the feedback response
[54, 55]. Thus, we tend to believe that the inhibitory
effect of propranolol on the feedback response is
achieved through a mechanism different from that
which modifies renin release.
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